Keep writing million scrips a year without any protections whatsoever? At some point you have to think about the future.
To Humphreys, the key point in favor of the reformulation — and other interventions that make opioid painkillers harder to misuse — is that they prevent more people from getting addicted to the drugs. After all, if the problem was that painkillers were so accessible that they made it easy for people to start on a path that ends with misusing and overdosing on heroin, then the inverse is true as well: Making opioid painkillers hard to obtain and misuse will stop people from going down a path of addiction.
On one hand, you have the current stock of opioid users who are addicted; the people in this population need treatment or they will simply find other, potentially deadlier opioids to use if they lose access to painkillers or the ability to misuse painkillers. On the other hand, you have to stop new generations of people from accessing and misusing opioids — or they will get addicted to the drugs and potentially overdose and die.
Consider the example given in the study: A person got addicted to opioids by misusing OxyContin, but when the formula for the pill changed, he lost his ability to misuse the drug, so he began using heroin instead. Part of this example shows the reformulation working as intended: The person was so burdened by the change that he felt the need to shift to heroin.
But what if addiction treatment was made very accessible? So when this person hit the roadblock to misusing opioids posed by the reformulation, he could have decided that it was time to get into an addiction treatment program, instead of going to heroin.
Apply that thousands of times over, and the findings of the paper could have been very different. The reality of the US today, though, is that treatment is not accessible enough for this to be realistic. In some states, for instance, waiting periods for treatment can span weeks or even months. Lieber agreed that this is plausible. But he argued that the findings of the paper still provide a lesson on the limitations — and dangerous side effects — of well-meaning interventions. Our mission has never been more vital than it is in this moment: to empower through understanding.
Financial contributions from our readers are a critical part of supporting our resource-intensive work and help us keep our journalism free for all. Please consider making a contribution to Vox today to help us keep our work free for all. Cookie banner We use cookies and other tracking technologies to improve your browsing experience on our site, show personalized content and targeted ads, analyze site traffic, and understand where our audiences come from.
By choosing I Accept , you consent to our use of cookies and other tracking technologies. The maker of OxyContin tried to make it harder to misuse. It may have led to more heroin deaths.
Reddit Pocket Flipboard Email. What the study found The study, which has not been peer reviewed yet, used economic models to measure trends in opioid overdose deaths — breaking them down to focus on heroin — to see what happened after the OxyContin reformulation was introduced in William Evans, Ethan Lieber, and Patrick Power The researchers looked at other potential explanations for these breaks in previous trends: if there was a sudden drop in the heroin price that may have led to more heroin use, whether new prescription drug monitoring databases may have cut off access to OxyContin and pushed people to heroin more so than the reformulation, and if the crackdown on Florida pill mills — which unscrupulously gave out opioid prescriptions — pushed people to heroin more than the reformulation.
This does not mean that making OxyContin harder to misuse was a bad idea Humphreys does not doubt that some people really did move on to heroin because of the OxyContin reformulation. Delivered Fridays. Thanks for signing up! Check your inbox for a welcome email. Email required. By signing up, you agree to our Privacy Notice and European users agree to the data transfer policy. For more newsletters, check out our newsletters page. The Latest. Why movies tilt the camera like this By Marie Cascione.
Soul food and the stories it tells about America By Jamil Smith. The Taliban, explained By Sam Ellis. Facebook is quietly buying up the metaverse By Peter Kafka. By , he was on OxyContin. His parents and siblings watched and worried as the strong, fastidiously neat man they knew became wobbly on his feet and unkempt.
He spent much of his day sleeping. He never awoke. He was A toxicology test showed lethal levels of oxycodone in his blood. Based on the date Gallego filled the prescription, there should have been 44 pills left. There were 7. By the late s, the patent on its main source of revenue, a morphine pill for cancer patients called MS Contin, was running out.
Executives anticipated a massive loss of revenue as generic versions drove down the price of MS Contin, according to internal company correspondence from the period. The company was focused on finding a new moneymaker. In a memo, Robert F. Kaiko, vice president for clinical research, laid out why it was important to develop a second painkiller. In this memo, Robert Kaiko, the scientist who would go on to help invent OxyContin, explains why Purdue needs another painkiller.
In MS Contin, the technique made morphine last eight to 12 hours. Kaiko and his colleagues decided to use it on an old, cheap narcotic, oxycodone. Sold under several names and formulations, including Percocet and Roxicodone, oxycodone controls pain for up to six hours.
Goldenheim,then-vice president of scientific and medical affairs, wrote in a court declaration. At a meeting, Purdue executives described how OxyContin could "cure" the "vulnerability" of generic competition and laid out how they planned to market the drug. The first patients to use OxyContin were women recuperating from abdominal and gynecological surgery at two hospitals in Puerto Rico in In the clinical study, designed and overseen by Purdue scientists and paid for by the company, 90 women were given a single dose of the drug while other patients were given short-acting painkillers or placebos.
None of the women were regular users of painkillers, so they were more susceptible to the effects of narcotics. Even so, more than a third of the women given OxyContin started complaining about pain in the first eight hours and about half required more medication before the hour mark, according to an FDA analysis of the study. The study found that OxyContin was safe, relieved pain and lasted longer than the short-acting painkillers.
Purdue moved ahead on two paths: seeking patents for its new drug and running additional clinical trials to secure FDA approval.
In study after study, many patients given OxyContin every 12 hours would ask for more medication before their next scheduled dose. A Tennessee pain specialist whom Purdue selected to field-test the drug in as part of the FDA approval process eventually moved 8 of 15 chronic pain patients to 8-hour dosing because they were not getting adequate relief taking the drug twice a day.
Robert Reder wrote to the Memphis physician, using medical shorthand for hour dosing. Narcotic painkillers work differently in different people. Some drug companies discuss that variability on their product labels and recommend that doctors adjust the frequency with which patients take the drugs, depending on their individual response. The morphine tablet, Kadian, manufactured by Actavis, is designed to be taken once a day, but the label states that some patients may need a dose every 12 hours.
It did not test OxyContin at more frequent intervals. To obtain FDA approval, Purdue had to demonstrate that OxyContin was safe and as effective as other pain drugs on the market. Under agency guidelines for establishing duration, the company had to show that OxyContin lasted 12 hours for at least half of patients. Purdue submitted the Puerto Rico study, which showed that. Officials at the agency declined to be interviewed.
After OxyContin hit the market in , ads in medical journals left no ambiguity about how long it lasted. A spotlight illuminated two dosage cups, one marked 8 AM and the other 8 PM. She had struggled with back pain since age 14, when she was thrown from a horse while practicing for an equestrian competition.
On that day in , her physician said he had something new for her to try. He told her to take OxyContin every 12 hours. Only the next pill would relieve her suffering. The change had little effect. For a year and a half, she spent each day cycling through misery and relief. Sometimes, she said, she contemplated suicide. Before OxyContin, doctors had viewed narcotic painkillers as dangerously addictive and primarily reserved their long-term use for cancer patients and the terminally ill.
Purdue envisioned a bigger market. Sales reps pitched the drug to family doctors and general practitioners to treat common conditions such as back aches and knee pain. With Percocet and other short-acting drugs, patients have to remember to take a pill up to six times a day, Purdue told doctors. The marketing succeeded in ways that astonished even Purdue executives.
It dwarfed them. The success of OxyContin brought a whole new level of wealth. Other drug companies began marketing their own narcotic painkillers for routine injuries. OxyContin accounted for a third of all sales revenue from painkillers that year, according to industry data. Rates of addiction and overdose have soared alongside the rise in prescriptions. News coverage of these problems in Appalachia and New England in the late s made OxyContin notorious.
Purdue dispatched representatives to Virginia, Maine and elsewhere to defend its drug. They blamed misuse of OxyContin and insisted their pill was a godsend for pain sufferers when taken as directed. David Haddox, told a reporter in The U.
Justice Dept. The company eventually rolled out a tamper-resistant version of the painkiller that was harder to crush and snort. Subscribe today for unlimited access to exclusive investigations, breaking news, features and more. But in all the scrutiny of Purdue and OxyContin, the problem of the drug wearing off early was not addressed. In reports to headquarters, they wrote that many physicians were prescribing it for three or even four doses a day. Lawrence Robbins started prescribing OxyContin at his Chicago migraine clinic shortly after it hit the market.
But insurance carriers often refused to cover the pharmacy bill for more than two pills a day, he said. Over the years, he wrote insurance companies more than 25 times on behalf of patients who he believed needed OxyContin more frequently than every 12 hours, he said.
In some cases, the insurers relented. When others did not, Robbins switched the patients to another drug. In this letter, a Purdue regional manager writes that he is concerned about doctors prescribing OxyContin at 8-hour intervals.
Sales reps should visit those physicians and convince them to go back to hour dosing, he writes. Data analyzed by company employees showed that one in five OxyContin prescriptions was for use every eight hours, or even more frequently. Purdue held closed-door meetings to retrain its sales force on the importance of hour dosing, according to training documents, some included in sealed court files and others described in FDA files.
In a petition to the FDA, attorneys for the state of Connecticut described the alarm inside Purdue when some doctors began prescribing OxyContin at more frequent intervals. There is no ceiling on the amount of OxyContin a patient can be prescribed, sales reps were to remind doctors, according to the presentation and other training materials.
After some physicians began prescribing OxyContin more frequently than every 12 hours, Purdue summoned its sales force to special seminars. As this presentation shows, company officials were concerned more frequent dosing would hurt business. Higher doses did mean more money for Purdue and its sales reps. Commissions and performance evaluations for the sales force were based in part on the proportion of sales from high-dose pills.
In this memo entitled "It's Bonus Time in the Neighborhood," a Purdue sales manager told her staff to talk up stronger doses of OxyContin in conversations with doctors. In the training materials reviewed by The Times, little was said about the effect of higher doses on patient health. Those on higher doses of opioids are more likely to overdose, according to numerous research studies. An analysis of the medical records of more than 32, patients on OxyContin and other painkillers in Ontario, Canada, found that one in 32 patients on high doses fatally overdosed.
As a varsity athlete at the University of Central Florida and later a public school teacher, Burgess MacNamara was used to following rules. That changed in when he had knee surgery and his doctor put him on OxyContin. Your whole day revolves around that.
Within a month, he was crushing and snorting the pills. Within a year, he was forging prescriptions.
0コメント